![Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC](https://oncodaily.com/pub/uploads/2024/01/IMG_1362-e1705607729995.jpeg)
Photo taken from Biagio Ricciuti/LinkedIn
Jan 18, 2024, 15:55
Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:
“Now out in the Journal of Clinical Oncology our effort to elucidate mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC. We identified acquired genomic and immunophenotypic changes that may contribute to the development of resistance to ICI +/- chemotherapy in patients with lung cancer.”
![Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC 1 Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC](https://oncodaily.com/pub/uploads/2024/01/IMG_1361.jpeg)
Additional information.
Source: Biagio Ricciuti/LinkedIn